Ovid Therapeutics to Participate in the JMP Securities 2017 Life Sciences Conference
June 12 2017 - 4:05PM
Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company
committed to developing medicines for patients with rare
neurological disorders, today announced that Yaron Werber, MD,
chief business and financial officer of Ovid, will participate in
the upcoming JMP Securities 2017 Life Sciences Conference.
Dr. Werber will participate in a panel discussion entitled “The
Emerging Landscape of Orphan / CNS Disorders” on Tuesday, June 20,
2017 at 1:00 p.m. EDT. The conference will be held at the St. Regis
Hotel in New York, NY.
About Ovid TherapeuticsOvid Therapeutics
(NASDAQ:OVID) is a New York-based, biopharmaceutical company using
its BoldMedicineTM approach to develop therapies that transform the
lives of patients with rare neurological disorders. Ovid’s drug
candidate, OV101, is currently in development for the treatment of
Angelman syndrome and Fragile X syndrome. Ovid has initiated the
Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a
Phase 1 trial in adolescents with Angelman syndrome or Fragile X
syndrome. Ovid is also developing OV935 in collaboration with
Takeda Pharmaceutical Company Limited for the treatment of rare
epileptic encephalopathies. Ovid expects to initiate a Phase
1b/2a trial of OV935 to treat rare epileptic encephalopathies in
2017.
For more information on Ovid, please visit
http://www.ovidrx.com/.
Ovid Contacts:
Investors:
Burns McClellan
Steve Klass, 212-213-0006
Sklass@burnsmc.com
Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
katie@purecommunicationsinc.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024